免疫治疗相关口腔不良事件的研究进展

doi:10.12337/zgkqjxjyzz.2025.06.001

中国口腔医学继续教育杂志 ›› 2025, Vol. 28 ›› Issue (6): 377-383.DOI: 10.12337/zgkqjxjyzz.2025.06.001

• 综述 • 下一篇

免疫治疗相关口腔不良事件的研究进展

童文锦^1,2, 卢锐^1,2,*

¹口颌系统重建与再生全国重点实验室,口腔生物医学教育部重点实验室,口腔医学湖北省重点实验室,武汉大学口腔医（学）院;
²武汉大学口腔医学院口腔黏膜科

出版日期:2025-11-30 发布日期:2025-11-30
通讯作者: ^*卢锐,联系方式：027-87686213,电子邮箱：lurui@whu.edu.cn;通讯地址：湖北省武汉市洪山区珞喻路237号,430079

Updates on the Immune-related Oral Adverse Events

Wenjin Tong^1,2, Rui Lu^1,2,*

¹State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School & Hospital of Stomatology, Wuhan University, Wuhan, Hubei Province, P.R.China;
²Department of Oral Medicine, School & Hospital of Stomatology, Wuhan University, Wuhan, Hubei Province, P.R.China

Online:2025-11-30 Published:2025-11-30
Contact: Rui Lu. Tel: 027-87686213. Email: lurui@whu.edu.cn. Address: Luoyu Road 237#, Wuhan 430079, Hubei Province, P.R.China.

摘要/Abstract

摘要： 免疫检查点抑制剂（immune-checkpoint inhibitors,ICIs）作为一种新型的抗肿瘤治疗方法,极大改善了许多晚期恶性肿瘤患者的预后。但随着临床应用的增加,其所导致的免疫治疗相关不良事件（immune-related adverse events,irAEs）也逐渐增多,并涉及全身各个器官系统,引起了临床学者们的广泛关注。迄今为止,关于口腔irAEs的研究及总结相对较少。本文将从口腔irAEs的临床病理特征和疾病管理现状等方面进行归纳总结,旨在为该类疾病的临床诊疗和相关研究提供参考。

关键词: 免疫检查点抑制剂, 免疫治疗相关不良事件, 口腔, 临床病理特征, 疾病管理

Abstract: As a novel anti-tumor therapeutic approach, immune-checkpoint inhibitors (ICIs) have significantly improved the prognosis of many patients with advanced malignancies. However, with increasing clinical application, immune-related adverse events (irAEs) induced by ICIs have become more frequent, involving various organ systems throughout the body and drawing extensive attention from clinical researchers. To date, studies and summaries focusing on oral irAEs remain relatively limited. This article summaries on the clinicopathological features and current management of oral irAEs, aiming to provide insights for clinical diagnosis, treatment and related research on such conditions.

Key words: immune-checkpoint inhibitors, immune-related adverse events, oral, clinicopathologic feature, disease management

童文锦, 卢锐. 免疫治疗相关口腔不良事件的研究进展[J]. 中国口腔医学继续教育杂志, 2025, 28(6): 377-383.

Wenjin Tong, Rui Lu. Updates on the Immune-related Oral Adverse Events[J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(6): 377-383.

参考文献

[1] Bagchi S, Yuan R, Engleman EG.Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance[J]. Annu Rev Pathol, 2021, 16:223-249.
[2] De Velasco G, Je Y, Bossé D, et al.Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients[J]. Cancer Immunol Res, 2017, 5(4):312-318.
[3] Xu Y, Wen N, Sonis ST, et al.Oral side effects of immune checkpoint inhibitor therapy (ICIT): An analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women’s Hospital, and the Dana-Farber Cancer Institute, 2011 to 2019[J]. Cancer, 2021, 127(11):1796-1804.
[4] de Oliveira Filho OV, Gibbons IL, Medeiros YL, et al. Oral and cutaneous immune-related adverse events in cancer patients: Prevalence and overall survival[J]. Oral Dis, 2025, 31(1):278-285.
[5] Villa A, Schneider BJ, Lacchetti C, et al.Oral Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors: Call to Action[J]. JCO Oncol Pract, 2025, 21(8):1073-1078.
[6] Elad S, Yarom N, Zadik Y, et al.The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies[J]. CA Cancer J Clin, 2022, 72(1):57-77.
[7] Jiang Q, Chen X, Wu J, et al.Oral Lichenoid lesions induced by programmed cell death protein 1 and cytotoxic T-lymphocyte-associated protein 4 bispecific antibody: a case report[J]. BMC Oral Health, 2024, 24(1):1240.
[8] Obara K, Masuzawa M, Amoh Y.Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: A report of two cases and published work review[J]. J Dermatol, 2018, 45(5):587-591.
[9] Klein BA, Alves FA, de Santana RVJ, et al. Oral manifestations of immune-related adverse events in cancer patients treated with immune checkpoint inhibitors[J]. Oral Dis, 2022, 28(1):9-22.
[10] Bhattacharyya I, Chehal H, Migliorati C.Severe oral erosive lichenoid reaction to pembrolizumab therapy[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2020, 130(5):e301-e307.
[11] Schaberg KB, Novoa RA, Wakelee HA, et al.Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy[J]. J Cutan Pathol, 2016, 43(4):339-346.
[12] Ramos-Casals M, Siso-Almirall A. Immune-Related Adverse Events of Immune Checkpoint Inhibitors[J]. Ann Intern Med, 2024, 177(2):ITC17-ITC32.
[13] Zhou G, Zhang J, Ren XW, et al.Increased B7-H1 expression on peripheral blood T cells in oral lichen planus correlated with disease severity[J]. J Clin Immunol, 2012, 32(4):794-801.
[14] Apalla Z, Nikolaou V, Fattore D, et al.European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force ‘Dermatology for cancer patients’ position statement[J]. J Eur Acad Dermatol Venereol, 2022, 36(3):332-350.
[15] Merli M, Accorinti M, Romagnuolo M, et al.Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience[J]. Front Med (Lausanne), 2023, 10:1208418.
[16] Yun JSW, Chan OB, Goh M, et al.Bullous pemphigoid associated with anti-programmed cell death protein 1 and anti-programmed cell death ligand 1 therapy: A case series of 13 patients[J]. Australas J Dermatol, 2023, 64(1):131-137.
[17] Sowerby L, Dewan AK, Granter S, et al.Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid[J]. JAMA Dermatol, 2017, 153(6):603-605.
[18] Zumelzu C, Alexandre M, Le Roux C, et al.Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature[J]. Front Med (Lausanne), 2018, 5:268.
[19] Sibaud V, Vigarios E, Siegfried A, et al.Nivolumab-related mucous membrane pemphigoid[J]. Eur J Cancer, 2019, 121:172-176.
[20] Shah KM, Rancour EA, Al-Omari A, et al. Striking enhancement at the site of radiation for nivolumab-induced Stevens-Johnson syndrome[J]. Dermatol Online J, 2018, 24(6):13030/qt97g3t63v.
[21] Yang F, Zhou P, Hua H.Severe oral and cutaneous immune-related adverse events induced by PD-1 inhibitors and antibody-drug conjugates: Case reports and management strategies[J]. Sci Prog, 2025, 108(3):368504251364109.
[22] Chwialkowska V, Slowinska M, Platkowska A, et al.Superficial mucoceles as a sequel to Stevens-Johnson syndrome during treatment of cutaneous squamous cell carcinoma with cemiplimab: A case report and review of literature[J]. Exp Ther Med, 2024, 29(1):15.
[23] Goldinger SM, Stieger P, Meier B, et al.Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy[J]. Clin Cancer Res, 2016, 22(16):4023-4029.
[24] Shazib MA, Woo SB, Sroussi H, et al.Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case series[J]. Oral Dis, 2020, 26(2):325-333.
[25] Shih T, Shih S, Sharaf M.Pembrolizumab-induced erythema multiforme requiring systemic immunosuppression[J]. Intern Med J, 2021, 51(12):2149-2150.
[26] Sundaresan S, Nguyen KT, Nelson KC, et al. Erythema multiforme major in a patient with metastatic melanoma treated with nivolumab[J]. Dermatol Online J, 2017, 23(9):13030/qt2513974h.
[27] Warner BM, Baer AN, Lipson EJ, et al.Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy[J]. Oncologist, 2019, 24(9):1259-1269.
[28] Vigarios E, Epstein JB, Sibaud V.Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors[J]. Support Care Cancer, 2017, 25(5):1713-1739.
[29] Wang S, Sun J, Deng S, et al.Lichen planus pemphigoides induced by anti-PD-1 antibody: A case only involved in oral mucosa with excellent topical treatment efficiency[J]. J Cutan Pathol, 2024, 51(2):114-118.
[30] Jonna S, Neiders M, Lakshmanan S, et al.Linear IgA Disease of the Gingiva Following Nivolumab Therapy[J]. J Immunother, 2019, 42(9):345-347.
[31] Sonoda T, Waseda Y, Iino S, et al. The case of non-small cell lung cancer followed by lip lymphoproliferative disease after immunotherapy[J]. Ann Oncol, 2019, 30(Suppl 6):vi142.
[32] Chen Q, Li D, Zhang G, et al.An immune-related adverse event of Behcet’s-like syndrome following pembrolizumab treatment[J]. BMC Pulm Med, 2024, 24(1):166.
[33] Yu Q, Wang WX.Camrelizumab (SHR-1210) leading to reactive capillary hemangioma in the gingiva: A case report[J]. World J Clin Cases, 2020, 8(3):624-629.
[34] Yun SJ, Oh IJ, Park CK, et al.Vitiligo-like depigmentation after pembrolizumab treatment in patients with non-small cell lung cancer: a case report[J]. Transl Lung Cancer Res, 2020, 9(4):1585-1590.
[35] Shah N, Cohen L, Seminario-Vidal L.Management of oral reactions from immune checkpoint inhibitor therapy: A systematic review[J]. J Am Acad Dermatol, 2020, 83(5):1493-1498.
[36] Xu Y, Wen N, Haddad RI, et al.Comparisons of Non-Oral Immune-Related Adverse Events Among Patients with Cancer with Different Oral Toxicity Profiles[J]. Oncologist, 2024, 29(3):e382-e391.

免疫治疗相关口腔不良事件的研究进展

Updates on the Immune-related Oral Adverse Events

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	孙齐瞻, 王宇峰. 口腔扁平苔藓中的T细胞免疫病理异质性研究现状[J]. 中国口腔医学继续教育杂志, 2025, 28(6): 384-392.
[2]	陈晓菊, 赵忠芳, 何肖翰, 刘斌. 复发性阿弗他溃疡粘附性药物递送研究进展[J]. 中国口腔医学继续教育杂志, 2025, 28(6): 393-397.
[3]	石妍, 乐迪, 邢海霞. 新疆与京津冀地区口腔医师艾滋病相关知识及态度的调查分析[J]. 中国口腔医学继续教育杂志, 2025, 28(6): 405-412.
[4]	田亚敏, 李宜宸, 丁伟. 复方丹参滴丸联合复方倍他米松治疗口腔黏膜下纤维性变1例[J]. 中国口腔医学继续教育杂志, 2025, 28(6): 422-427.
[5]	石红柯, 邓舒之, 史雪珂, 周红梅. 慢性移植物抗宿主病相关口腔苔藓样损害1例[J]. 中国口腔医学继续教育杂志, 2025, 28(6): 444-450.
[6]	董馨怡, 李敏, 王柳, 卢珊, 陈方淳. 多学科联合诊疗口腔红白斑1例[J]. 中国口腔医学继续教育杂志, 2025, 28(6): 451-459.
[7]	韩莹, 闫志敏, 魏攀, 华红, 刘宏伟. 分层递进培养模式在口腔黏膜病学临床教学中的应用探索[J]. 中国口腔医学继续教育杂志, 2025, 28(6): 469-474.
[8]	徐冰玥, 鲁涵, 刘柯蓥, 何巍. 药物相关性颌骨坏死中微生态失衡的研究进展[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 312-321.
[9]	那颖旭, 钱锟. 人工智能在口腔医学诊断研究中的应用现状[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 337-344.
[10]	释栋, 于晨浩, 司燕, 宋忠臣, 欧阳翔英, 刘怡, 胡文杰, 潘亚萍. 中国牙周健康管理现状与未来策略[J]. 中国口腔医学继续教育杂志, 2025, 28(4): 189-193.
[11]	俞建宇, 徐淑兰. 口腔种植科诊疗中的感染控制[J]. 中国口腔医学继续教育杂志, 2025, 28(2): 67-75.
[12]	徐丹慧, 丁建芬, 林海燕, 胡凯, 辛子熙, 刘翠梅, 朱洪平. 口腔颌面外科住院患者的医院感染监测与控制[J]. 中国口腔医学继续教育杂志, 2025, 28(2): 76-82.
[13]	吕晨浩, 朱晓鸣, 谭瑶, 常青, 李德利, 钱军, 唐志辉, 谭建国. 面部引导的口腔美学虚拟教学在口腔教学中的应用[J]. 中国口腔医学继续教育杂志, 2025, 28(2): 83-88.
[14]	丁建芬, 胡凯, 辛子熙, 徐丹慧, 林海燕, 朱洪平. 某三级口腔专科医院口腔医师职业暴露情况调查分析[J]. 中国口腔医学继续教育杂志, 2025, 28(2): 89-95.
[15]	贾丽永, 陈琼, 宋阳阳. 瑞马唑仑联合瑞芬太尼对口腔颌面外科手术的影响[J]. 中国口腔医学继续教育杂志, 2025, 28(1): 12-17.